Topline data in mid-2028 means no binary catalyst for ~2 years. Watch for oral ribupatide Phase 3 initiation in H1 2027 as the next potential catalyst. Near-term stock movement likely driven by broader obesity sector sentiment and pipeline updates from competitors.
Price Chart
Executive Summary
Kailera Therapeutics completed enrollment in its KaiNETIC global Phase 3 program for ribupatide injection (KAI-9531), a once-weekly dual GLP-1/GIP agonist for obesity. Topline data from all three trials (KaiNETIC-1, -2, -3) are now expected in mid-2028, pushing the next major catalyst nearly two years out. This is a routine operational milestone with no new efficacy or safety data, and the extended timeline reduces near-term upside.
Key Facts
- Enrollment completed across all three KaiNETIC Phase 3 trials (KaiNETIC-1, -2, -3) evaluating ribupatide injection for obesity/overweight.
- Topline data now expected in mid-2028, extended from prior expectations.
- KaiNETIC-1 enrolled ~2,500 adults (BMI ≥30 or ≥27 with comorbidity, excluding T2D); primary endpoint is % body weight change at Week 76.
- KaiNETIC-2 enrolled ~1,200 adults (BMI ≥27 with T2D); co-primary endpoints are % body weight change and HbA1c change at Week 76.
- KaiNETIC-3 enrolled ~1,200 adults (BMI ≥35 without T2D); co-primary endpoints are % body weight change vs placebo and vs semaglutide 2.4 mg at Week 76.
- Ribupatide doses up to 10 mg administered weekly; trials conducted at >200 sites across 11 countries.
- Hengrui submitted an NDA to China's NMPA for long-term weight management; Kailera holds ex-Greater China rights.
- Kailera plans to initiate global Phase 3 trials for once-daily oral ribupatide in H1 2027.
Financial Impact
No financial data provided. Enrollment completion is an operational milestone with no revenue or cost figures disclosed.
Risk Factors
- Extended timeline to mid-2028 for pivotal data leaves stock exposed to sector sentiment and competitor developments.
- Phase 3 failure risk remains; ribupatide must demonstrate non-inferiority or superiority vs semaglutide in KaiNETIC-3.
- Dependence on Hengrui for manufacturing and China regulatory progress; any delays there could impact Kailera's timeline.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371745 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $11.03 | awaiting T+20 | — | $13.13 (+19.04%) |
Sep 30, 2026 27d ago | Press Release | $11.42 | awaiting T+20 | — | $13.13 (+14.97%) |
Sep 9, 2026 6w ago | 3 | $14.91 $10.00 | ▼ −32.93% | ▼ −35.06% | $13.13 (−11.94%) |
Aug 12, 2026 10w ago | 8-K | $17.97 | awaiting T+20 | — | $13.13 (−26.93%) |
Jul 31, 2026 12w ago | Court Ruling | $16.94 | awaiting T+20 | — | $13.13 (−22.49%) |
Jul 24, 2026 13w ago | Court Ruling | $17.48 $16.54 | ▼ −5.38% | ▼ −8.68% | $13.13 (−24.89%) |
Jun 5, 2026 20w ago | Press Release | $19.70 $23.30 | ▲ +18.27% | ▲ +16.64% | $13.13 (−33.35%) |
May 26, 2026 22w ago | 8-K | $21.91 $20.66 | ▼ −5.71% | ▼ −3.80% | $13.13 (−40.07%) |
May 26, 2026 22w ago | Press Release | $21.91 $20.66 | ▼ −5.71% | ▼ −3.80% | $13.13 (−40.07%) |
May 13, 2026 23w ago | Press Release | $21.11 $19.54 | ▼ −7.44% | ▼ −6.82% | $13.13 (−37.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers